Suggested remit: To appraise the clinical and cost effectiveness of zuranolone within its marketing authorisation for treating severe postnatal depression.
- Status:
- In progress
- Technology type:
- Medicine
- Decision:
- Selected
- Reason for decision:
- Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in use addressed, and help them make the best use of NHS resources
- Process:
- STA Standard
- ID number:
- 6431
Project Team
- Project lead
- Jeremy Powell
Email enquiries
If you have any queries please email [email protected]
- External Assessment Group:
- Bristol Technology Assessment Group, University of Bristol
Stakeholders
- Companies sponsors
- Biogen (zuranolone)
- Others
- Department of Health and Social Care
- NHS England
- Professional groups
- College of Mental Health Pharmacy
- Royal College of Physicians
- UK Clinical Pharmacy Association
- Associated public health groups
- Public Health Wales
- UK Health Security Agency
- Comparator companies
- Accord Healthcare (amitriptyline, citalopram, duloxetine, escitalopram, imipramine, lofepramine, mirtazapine, fluoxetine, paroxetine, quetiapine, sertraline and venlafaxine) CAU not received- not participating
- Amneal Pharma Europe (duloxetine, paroxetine) CAU not received- not participating
- Arristo Pharma (quetiapine) CAU not received- not participating
- AstraZeneca (quetiapine) CAU not received- not participating
- Aurobindo Pharma (citalopram, duloxetine, escitalopram, fluoxetine, mirtazapine, paroxetine, quetiapine, sertraline and venlafaxine) CAU not received- not participating
- Chiesi (venlafaxine) CAU not received- not participating
- Consilient Health (duloxetine, escitalopram, quetiapine and venlafaxine) CAU not received- not participating
- Creo Pharma (lofepramine and trazodone) CAU not received- not participating
- Dexcel Pharma (venlafaxine) CAU not received- not participating
- Dr Reddys Labs (duloxetine, fluoxetine and sertraline) CAU not received- not participating
- Fontus heath (quetiapine) CAU not received- not participating
- GlaxoSmithKline (paroxetine) CAU not received- not participating
- HBS Healthcare (duloxetine) CAU not received- not participating
- Kyowa Kirin (phenelzine) CAU not received- not participating
- Lilly UK (duloxetine and fluoxetine) CAU not received- not participating
- Lundbeck (citalopram, escitalopram, vortioxetine) CAU not received- not participating
- Lupin (sertraline) CAU not received- not participating
- Marlborough (doxepin) CAU not received- not participating
- Merck Sharp & Dohme (mirtazapine) CAU not received- not participating
- Mylan (citalopram, clomipramine, escitalopram, fluoxetine, fluvoxamine, lofepramine, mianserin, mirtazapine, paroxetine, quetiapine, trazodone and venlafaxine) CAU not received- not participating
- Par Laboratories Europe (fluoxetine) CAU not received- not participating
- Pfizer (reboxetine, sertraline and venlafaxine) CAU not received- not participating
- Rivopharm (citalopram, trazodone) CAU not received- not participating
- Sandoz (citalopram, paroxetine and quetiapine) CAU not received- not participating
- Servier (agomelatine) CAU not received- not participating
- SilverCloud (Space from Depression) CAU not received- not participating
- Sun Pharmaceuticals (sertraline and venlafaxine) CAU not received- not participating
- Teva UK (amitriptyline, citalopram, clomipramine, fluoxetine, fluvoxamine, imipramine, lofepramine, mianserin, mirtazapine, paroxetine, sertraline, trazodone and venlafaxine) CAU not received- not participating
- Wockhardt (amitriptyline, fluoxetine, fluvoxamine, mirtazapine and venlafaxine) CAU not received- not participating
- Zentiva (citalopram, duloxetine, escitalopram, quetiapine, trazodone and trimipramine) CAU not received- not participating
- General commentators
- All Wales Therapeutics and Toxicology Centre
- British National Formulary
- Department of Health - Northern Ireland
- Healthcare Improvement Scotland
- Medicines and Healthcare products Regulatory Agency
- Scottish Medicines Consortium
- Welsh Government
- Welsh Health Specialised Services Committee
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 28 August 2025 - 18 September 2025 | Draft guidance: 1 |
| 06 August 2025 | Committee meeting |
| 06 August 2025 | Declaration of interests |
| 09 January 2025 | Invitation to participate |
| 11 November 2024 (14:00) | Scoping workshop |
| 16 September 2024 - 14 October 2024 | Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators: 6431 |
| 16 September 2024 | In progress. Scoping commencing |
| 07 June 2023 | Awaiting development. Status change linked to Topic Selection Decision being set to Selected |
For further information on our processes and methods, please see our CHTE processes and methods manual